TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant.

Slides:

Advertisements

Similar presentations

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Advertisements

Slide 1 Increased Risk of Ischemic Events Upon Discontinuation of Prasugrel After 12 or 30 Months of Therapy Following Placement of the TAXUS Liberté Paclitaxel-

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.

PRODIGY Objective Study Design Primary Composite Endpoint

Individualizing Treatment Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Analysis from the DAPT Study Robert W. Yeh,

Embargoed Until 10:45 a.m. ET, Tuesday, Nov. 10, 2015

NSTE Acute Coronary Syndromes

WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.

Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) Trial Presented at The American College of Cardiology Scientific Session.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Impact of Low-molecular-weight Heparin (Reviparin) on Mortality, Reinfarction, and Stroke in Patients with Acute MI CREATE-ECLA - Reviparin Presented at:

DAPT Mortality and Cancer: Focus on HIRA Database

Disclosures Speaker’s bureau: Research support: Consulting: Equity

Stent Thrombosis and Optimal Duration of DAPT

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

For the HORIZONS-AMI Investigators

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

DES Should be Used as the Default Stent in ACS!

ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.

POISE-2 PeriOperative ISchemic Evaluation-2 Trial

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

What is the DAPT Score? Robert W. Yeh, MD MSc MBA

European and US Guidelines

(p < for group 1 or 2 vs. group 3)

Preventing Thrombotic Complications in ACS: State of the Art

Oral Anticoagulation and Preventing Stent Thrombosis

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

NOACs, AF, and PCI: What Do the Latest Data Suggest?

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Glenn N. Levine et al. JACC 2016;68:

Table. Clinical Efficacy and Safety

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

What Has Been Tried and What Is True?

Antiplatelet Therapy and Secondary Prevention

Terms of Use. Terms of Use.

NOACS: Emerging data in ACS/IHD

AF and PCI in Practice.

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

Nat. Rev. Cardiol. doi: /nrcardio

LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.

BASKET-SAVAGE Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were.

For the HORIZONS-AMI Investigators

For the HORIZONS-AMI Investigators

ISAR-SAFE Trial design: Patients with DES PCI received 6 months of open-label DAPT with aspirin and clopidogrel. At 6 months, they were randomized in a.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Duration of Dual Antiplatelet Therapy

American Heart Association Presented by Dr. Julinda Mehilli

Ezetimibe/simvastatin

IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.

Ischemic Postconditioning

Overall (n=301) Acute/Subacute (n=149) Late (n=152) p Presentation

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

BRIGHT Trial design: Patients undergoing PCI for ACS were randomized in a 1:1:1 fashion to receive either bivalirudin alone, unfractionated heparin (UFH)

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Primary safety endpoint

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

Section C: Clinical trial update: Oral antiplatelet therapy

Antithrombotic Therapy in AF Patients Undergoing PCI

Presentation transcript:

TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant at 1 year, were randomized to further 18 months of dual antiplatelet therapy (DAPT) or placebo. They were followed for 18 months. Results (p < 0.001) MACCE for DAPT vs. placebo: 3.7% vs. 8.8%, HR 0.41, 95% CI 0.28-0.59, p < 0.001 MI: 1.9% vs. 7.1%, p < 0.001; stent thrombosis: 0.2% vs. 2.9%, p < 0.001; all-cause mortality: 2.0% vs. 1.9%, p = 0.85 GUSTO moderate/severe bleeding: 2.4% vs. 1.7%, p = 0.23 % Conclusions Prolonged DAPT with aspirin and prasugrel for 30 months following index PCI with Taxus Liberté PES results in lower stent thrombosis and recurrent MIs compared with a 12-month duration of DAPT, with similar rates of bleeding and all-cause mortality This is not a separate clinical trial, but a subset of the DAPT trial; this appears to be the subset with the clearest benefit MACCE DAPT (n = 1,098) Placebo (n = 1,093) Presented by Dr. Kirk Garratt at AHA 2014